Literature DB >> 28345360

The effects of multimodal rehabilitation on pain-related sickness absence - an observational study.

Hillevi Busch1, Elisabeth Björk Brämberg2, Jan Hagberg2, Lennart Bodin2, Irene Jensen2.   

Abstract

PURPOSE: The aim of the current study was to examine the effects on sickness absence of multimodal rehabilitation delivered within the framework of a national implementation of evidence based rehabilitation, the rehabilitation guarantee for nonspecific musculoskeletal pain.
METHOD: This was an observational matched controlled study of all persons receiving multimodal rehabilitation from the last quarter of 2009 until the end of 2010. The matching was based on age, sex, sickness absence the quarter before intervention start and pain-related diagnosis. The participants were followed by register data for 6 or 12 months. The matched controls received rehabilitation in accordance with treatment-as-usual.
RESULTS: Of the participants, 54% (N = 3636) were on registered sickness absence at baseline and the quarter before rehabilitation. The average difference in number of days of sickness absence between the participants who received multimodal rehabilitation and the matched controls was to the advantage of the matched controls, 14.7 days (CI 11.7; 17.7, p ≤ 0.001) at 6-month follow-up and 9.5 days (CI 6.7; 12.3, p ≤ 0.001) at 12-month follow-up. A significant difference in newly granted disability pensions was found in favor of the intervention.
CONCLUSIONS: When implemented nationwide, multimodal rehabilitation appears not to reduce sickness absence compared to treatment-as-usual. Implications for Rehabilitation A nationwide implementation of multimodal rehabilitation was not effective in reducing sickness absence compared to treatment-as-usual for persons with nonspecific musculoskeletal pain. Multimodal rehabilitation was effective in reducing the risk of future disability pension for persons with nonspecific musculoskeletal pain compared to treatment-as-usual. To be effective in reducing sick leave multimodal rehabilitation must be started within 60 days of sick leave. The evidence for positive effect of multimodal rehabilitation is mainly for sick listed patients. Prevention of sick leave for persons not being on sick leave should not be extrapolated from evidence for multimodal rehabilitation.

Entities:  

Keywords:  Multimodal rehabilitation; observational study; sick leave

Mesh:

Year:  2017        PMID: 28345360     DOI: 10.1080/09638288.2017.1305456

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  4 in total

Review 1.  A scoping review to ascertain the parameters for an evidence synthesis of psychological interventions to improve work and wellbeing outcomes among employees with chronic pain.

Authors:  Joanna L McParland; Pamela Andrews; Lisa Kidd; Lynn Williams; Paul Flowers
Journal:  Health Psychol Behav Med       Date:  2021-01-28

Review 2.  Treatment Efficacy, Clinical Utility, and Cost-Effectiveness of Multidisciplinary Biopsychosocial Rehabilitation Treatments for Persistent Low Back Pain: A Systematic Review.

Authors:  Cornelia Rolli Salathé; Markus Melloh; Rebecca Crawford; Stephanie Scherrer; Norbert Boos; Achim Elfering
Journal:  Global Spine J       Date:  2018-04-19

3.  Evaluation of a multimodal pain rehabilitation programme in primary care based on clinical register data: a feasibility study.

Authors:  Charlotte Post Sennehed; Kjerstin Stigmar; Birgitta Grahn; Marcelo Rivano Fischer; Malin Forsbrand; Anja Nyberg; Ingemar F Petersson; Sara Holmberg
Journal:  Prim Health Care Res Dev       Date:  2020-01-14       Impact factor: 1.458

4.  Prevention of sickness absence through early identification and rehabilitation of at-risk patients with musculoskeletal pain (PREVSAM): a randomised controlled trial protocol.

Authors:  Meh Larsson; L Nordeman; K Holmgren; A Grimby-Ekman; G Hensing; C Björkelund; S Bergman; A Ekhammar; M Dottori; S Bernhardsson
Journal:  BMC Musculoskelet Disord       Date:  2020-11-28       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.